These findings are consistent with previous studies implicating MXD3 dysregulation in various human malignancies, including leukemia, liver cancer, renal cancer, and glioma, highlighting the broad relevance of MXD3 in cancer biology [13–19]. This evidence concerns the gene MXD3 and leukemia.